Article Details

Cassava, Biogen lead Alzheimer's stocks higher following Roche's gantenerumab setback

Retrieved on: 2022-11-14 22:16:28

Tags for this article:

Click the tags to see associated articles and topics

Cassava, Biogen lead Alzheimer's stocks higher following Roche's gantenerumab setback. View article details on hiswai:

Excerpt

Several pharma and biotech companies working on Alzheimer's treatments are up in Monday trading after Roche reported its candidate gantenerumab ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up